[
  {
    "ts": "2026-02-23T09:09:00+00:00",
    "headline": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
    "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
    "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3c7651a1-95a3-332a-b998-5a03aae2a9eb",
      "content": {
        "id": "3c7651a1-95a3-332a-b998-5a03aae2a9eb",
        "contentType": "STORY",
        "title": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
        "description": "",
        "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
        "pubDate": "2026-02-23T09:09:00Z",
        "displayTime": "2026-02-23T09:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]